Medtronic (MDT) just released its Q3 2026 results, reporting revenue ahead of expectations and solid contributions from its cardiovascular and diabetes businesses. Management also reaffirmed full year guidance, even as costs and tariffs remain a headwind.

Medtronic’s share price has been choppy in recent months, with a 2.16% 1 day share price gain after the Q3 release, but only a 1.79% 30 day share price return and a 0.87% 90 day share price decline. Its 1 year total shareholder return of 16.78% suggests longer term holders have seen steadier progress than recent traders.

If Medtronic’s robotics and cardiovascular news has your attention, it could be a good time to look at 25 healthcare AI stocks as another way to find healthcare names using AI in meaningful ways.

With Medtronic trading at $98.49, carrying a small intrinsic premium and a discount to the average analyst target, the key question is whether recent product wins and revenue momentum leave upside on the table or if future growth is already reflected in the valuation.

Most Popular Narrative: 3.7% Overvalued

According to the most followed narrative, Medtronic's fair value sits at $95.00, a touch below the recent $98.49 close, which frames the current debate around upside.

Strengths and Competitive Advantages: Diverse Product Portfolio: Medtronic operates across four key segments: Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes, providing revenue stability and reducing dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics). Robust R&D and Innovation: With an annual R&D investment of approximately $2.7 billion (9% of revenue), Medtronic maintains a strong pipeline, including breakthroughs like the Hugo robotic-assisted surgery system (competing with Intuitive Surgical’s da Vinci) and the MiniMed 780G insulin pump. Recent FDA approvals, such as the PulseSelect AF ablation system, underscore innovation momentum.

Curious how a diversified device portfolio plus heavy R&D spending adds up to that $95.00 fair value? The narrative leans on product breadth, international reach, and assumed profitability strength. The real story sits in the exact growth, margin, and return assumptions behind that number.

Result: Fair Value of $95.00 (OVERVALUED)

However, this hinges on Medtronic avoiding major regulatory setbacks or product recalls, and on the underperforming diabetes unit not dragging on group profitability assumptions.

Another View: Earnings Multiple Paints a Different Picture

While the narrative pegs fair value at $95.00 and calls Medtronic slightly overvalued, the current P/E of 27.4x sits well below the fair ratio of 36x, the US Medical Equipment average of 30.3x, and the peer average of 44x. That gap suggests the market might be pricing in extra risk or simply being cautious. The question is which story you place more weight on.

Next Steps

If this mix of caution and optimism around Medtronic resonates with you, take a moment to review the numbers yourself and decide where you stand, then weigh up the 5 key rewards and 2 important warning signs to see how others are thinking about the balance between concern and opportunity.

Ready to hunt for your next idea?

If Medtronic is on your radar, do not stop there. Use the Simply Wall St screener to uncover other opportunities that fit your style before they move.

• Target dependability in your income plan by scanning companies we flag as potential 13 dividend fortresses that might suit a yield focused watchlist.
• Spot potential mispricings quickly by filtering for 53 high quality undervalued stocks that pair quality fundamentals with what could be appealing valuations.
• Prioritise resilience by concentrating on 80 resilient stocks with low risk scores that our checks suggest have fewer red flags than many peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.